Clonazepam NDC 0093-9293

NDC codes

FDA NDC Directory

Product NDC (as listed)0093-9293Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00093-9293Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0093-9293-67	00093929367	60 BLISTER PACK in 1 CARTON (0093-9293-67) / 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACKMarketed from Nov 22, 2021

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Clonazepam
Generic name (nonproprietary): clonazepam
Active ingredients: Clonazepam — 1 mg/1
Dosage form: Tablet, Orally disintegrating
Route: Oral
Labeler: Teva Pharmaceuticals USA, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 077194
Marketing start: Nov 22, 2021
Listing expires: Dec 31, 2026
DEA schedule: CIV
Other FDA classes: Benzodiazepines (Chemical structure)
Identifiers: Product ID 0093-9293_a2f2eb5b-f890-4d6d-b728-5f63eb7dc11cSPL ID a2f2eb5b-f890-4d6d-b728-5f63eb7dc11cSPL set ID cb2e209e-e69b-422b-8abb-34df2bc92caaRxCUI 349194, 349195, 349196, 349197, 349198UNII 5PE9FDE8GB
Pharmacologic class: Benzodiazepine

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400093929367 followed by a unit qualifier and the quantity

Package 00093-9293-67. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 14, 2024. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Seizure Disorders Clonazepam orally disintegrating tablets are useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam orally disintegrating tablets may be useful. In some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within 3 months of administration. In some cases, dosage adjustment may reestablish efficacy. Panic Disorder Clonazepam orally disintegrating tablets are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DS…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 077194

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 077194
Product	Strength	Form · route	Labeler	Product NDC
Clonazepam	Clonazepam .125 mg/1	Tablet, Orally disintegratingOral	Teva Pharmaceuticals USA, Inc.	0093-9290
Clonazepam	Clonazepam .25 mg/1	Tablet, Orally disintegratingOral	Teva Pharmaceuticals USA, Inc.	0093-9291
Clonazepam	Clonazepam .5 mg/1	Tablet, Orally disintegratingOral	Teva Pharmaceuticals USA, Inc.	0093-9292
Clonazepam	Clonazepam 2 mg/1	Tablet, Orally disintegratingOral	Teva Pharmaceuticals USA, Inc.	0093-9294